{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:57:48Z","timestamp":1790683068148,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To estimate the clinical effectiveness of oseltamivir in children with different subtypes of influenza virus infection.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 998 children with acute respiratory infection were enrolled from January to March 2018, and were divided into influenza A, influenza B, influenza A + B, and non-influenza infection (IV-negative) groups. Influenza-like symptoms and duration of fever were evaluated and compared between oseltamivir-treated and non-treated groups.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> There were no significant differences in the reduction in total febrile period and duration of fever from the onset of therapy between the oseltamivir treated and non-treated children infected with influenza A (<jats:italic>p<\/jats:italic> = 0.6885 for total febrile period and 0.7904 for the duration of fever from the onset of treatment), influenza B (<jats:italic>p<\/jats:italic> = 0.1462 and 0.1966), influenza A + B (<jats:italic>p<\/jats:italic> = 0.5568 and 0.9320), and IV-negative (<jats:italic>p<\/jats:italic> = 0.7631 and 0.4655). The duration of fever in children received oseltamivir therapy within 48\u00a0h was not significantly shorter than that beyond 48\u00a0h (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Additionally, percentages and severities of influenza-like symptoms, including headache, myalgia, fatigue, bellyache, vomiting, diarrhea, sore throat, cough, and coryza were not decreased and alleviated after treatment of oseltamivir.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Oseltamivir treatment does not significantly shorten the duration of fever, nor does it significantly relieve influenza-like symptoms in children with infection of influenza.<\/jats:p>","DOI":"10.3389\/fphar.2022.849545","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T05:39:14Z","timestamp":1649223554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children"],"prefix":"10.3389","volume":"13","author":[{"given":"Jianru","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1186\/1471-2458-12-968","article-title":"Burden of Paediatric Influenza in Western Europe: a Systematic Review","volume":"12","author":"Antonova","year":"2012","journal-title":"Bmc Public Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s12519-021-00432-1","article-title":"Distinctive Clinical and Laboratory Features of COVID-19 and H1N1 Influenza Infections Among Hospitalized Pediatric Patients","volume":"17","author":"Asseri","year":"2021","journal-title":"World J. Pediatr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.antiviral.2021.105092","article-title":"Virological and Clinical Outcomes in Outpatients Treated with Baloxavir or Oseltamivir: A Japanese Multicenter Study in the 2019-2020 Influenza Season","volume":"192","author":"Chong","year":"2021","journal-title":"Antivir. Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"II5","DOI":"10.1093\/jac\/dkq015","article-title":"Pharmacokinetics of Oseltamivir: an Oral Antiviral for the Treatment and Prophylaxis of Influenza in Diverse Populations","author":"Davies","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1586\/17476348.2016.1126182","article-title":"Oseltamivir for Influenza Infection in Children: Risks and Benefits","volume":"10","author":"Esposito","year":"2016","journal-title":"Expert Rev. Respir. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.02.005","article-title":"Effectiveness of Favipiravir (T-705) against Wild-type and Oseltamivir-Resistant Influenza B Virus in Mice","volume":"545","author":"Fang","year":"2020","journal-title":"Virology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3201\/eid1712.111002","article-title":"A Pilot Study of Host Genetic Variants Associated with Influenza-Associated Deaths Among Children and Young Adults","volume":"17","author":"Ferdinands","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"106155","DOI":"10.1016\/j.ijantimicag.2020.106155","article-title":"Effectiveness of Oseltamivir in Reduction of Complications and 30-day Mortality in Severe Seasonal Influenza Infection","volume":"56","author":"Groeneveld","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10822-019-00251-7","article-title":"Source of Oseltamivir Resistance Due to Single E119D and Double E119D\/H274Y Mutations in pdm09H1N1 Influenza Neuraminidase","volume":"34","author":"Hanpaibool","year":"2020","journal-title":"J. Comput. Aided Mol. Des."},{"key":"B10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1086\/656408","article-title":"Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age: A Randomized Controlled Trial","volume":"51","author":"Heinonen","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.chom.2017.09.008","article-title":"A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets","volume":"22","author":"Imai","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B12","doi-asserted-by":"publisher","first-page":"g2545","DOI":"10.1136\/bmj.g2545","article-title":"Oseltamivir for Influenza in Adults and Children: Systematic Review of Clinical Study Reports and Summary of Regulatory Comments","volume":"348","author":"Jefferson","year":"2014","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.9758\/cpn.2021.19.1.166","article-title":"Delayed Onset of Manic Symptoms in a Patient with Influenza A (H1N1) after Administration of Oseltamivir (Tamiflu): A Case Report","volume":"19","author":"Jhon","year":"2021","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1086\/505868","article-title":"A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003-2004 and 2004-2005 Influenza Seasons","volume":"43","author":"Kawai","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/jcm10020273","article-title":"Favipiravir in Therapy of Viral Infections","volume":"10","author":"\u0141agocka","year":"2021","journal-title":"Jcm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800118","article-title":"Mortality Attributable to Seasonal Influenza in Greece, 2013 to 2017: Variation by Type\/subtype and Age, and a Possible Harvesting Effect","volume":"24","author":"Lytras","year":"2019","journal-title":"Euro Surveill."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13542","DOI":"10.1111\/tid.13542","article-title":"Baloxavir Treatment of Oseltamivir-Resistant Influenza A\/H1pdm09 in Two Immunocompromised Patients","volume":"23","author":"Macesic","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/irv.12844","article-title":"Re-emergence of Influenza Virus Circulation during 2020 in Parts of Tropical Asia: Implications for Other Countries","volume":"15","author":"Mott","year":"2021","journal-title":"Influenza Other Respir. Viruses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of Neuraminidase Inhibitors in Reducing Mortality in Patients Admitted to Hospital with Influenza A H1N1pdm09 Virus Infection: a Meta-Analysis of Individual Participant Data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJM200001273420401","article-title":"The Effect of Influenza on Hospitalizations, Outpatient Visits, and Courses of Antibiotics in Children","volume":"342","author":"Neuzil","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1086\/656439","article-title":"Recovery of a Multidrug-Resistant Strain of Pandemic Influenza A 2009 (H1N1) Virus Carrying a Dual H275Y\/I223R Mutation from a Child after Prolonged Treatment with Oseltamivir","volume":"51","author":"Nguyen","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"E959","DOI":"10.1093\/cid\/ciaa1689","article-title":"Estimates of Inactivated Influenza Vaccine Effectiveness Among Children in Senegal: Results from 2 Consecutive Cluster-Randomized Controlled Trials in 2010 and 2011","volume":"72","author":"Niang","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/jpids\/piaa145","article-title":"Baloxavir Treatment in Adolescents with Acute Influenza: Subgroup Analysis from the CAPSTONE-1 Trial","volume":"10","author":"Portsmouth","year":"2021","journal-title":"J. Pediatr. Infect Dis Soc"},{"key":"B24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/pds.3707","article-title":"A Prospective Observational Study of Oseltamivir Safety and Tolerability in Infants and Young Children \u226424\u2009months","volume":"24","author":"Rath","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/cid\/ciz075","article-title":"Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season","volume":"69","author":"Rolfes","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ajem.2020.12.081","article-title":"Rapid and Severe Neurologic Deterioration Due to Influenza Associated Encephalopathy in a Healthy Child","volume":"45","author":"Roth","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/IDR.S153154","article-title":"Antiviral Resistance Markers in Influenza Virus Sequences in Mexico, 2000-2017","volume":"11","author":"Toledo-Rueda","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"B28","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12325-012-0050-8","article-title":"Post-marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review","volume":"29","author":"Toovey","year":"2012","journal-title":"Adv. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1080\/07391102.2020.1747550","article-title":"An Effective Molecular Blocker of Ion Channel of M2 Protein as Anti-influenza a Drug","volume":"39","author":"Vorobjev","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B30","doi-asserted-by":"publisher","first-page":"CD002744","DOI":"10.1002\/14651858.CD002744.pub4","article-title":"Neuraminidase Inhibitors for Preventing and Treating Influenza in Children (Published Trials Only)","author":"Wang","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy versus Oseltamivir Monotherapy in Critically Ill Patients with Influenza Virus Infection","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fimmu.2018.01547","article-title":"Advancements in Host-Based Interventions for Influenza Treatment","volume":"9","author":"Yip","year":"2018","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/acem.14241","article-title":"Neuraminidase Inhibitors for Treatment of Influenza","volume":"28","author":"Zwillenberg","year":"2021","journal-title":"Acad. Emerg. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.849545\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T05:39:17Z","timestamp":1649223557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.849545\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":33,"alternative-id":["10.3389\/fphar.2022.849545"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.849545","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"article-number":"849545"}}